Abstract
COVID-19 primarily targets the angiotensin-converting enzyme 2 (ACE2) receptor, which enables the virus to infiltrate host cells via the spike glycoprotein. In this research, Thailandiol could serve as a dual inhibitor for the spike glycoprotein and the interface of the spike glycoprotein and ACE2. This was achieved using molecular docking and ADMET analysis. We docked Thailandiol against the crystal structures of the spike glycoprotein and the Receptor Binding Domain region of SARS-CoV-2 and the ACE2 receptor using AutoDock4 & Vina. Thailandiol demonstrated high binding affinity and favourable interactions with both the spike glycoprotein and the RBD region. Additionally, Thailandiol exhibited favourable ADMET properties and Swiss target prediction. Our in-silico research indicates that Thailandiol has the potential to be a dual inhibitor for the spike glycoprotein and the interface of the RBD region, and could be developed into a novel therapeutic agent for COVID-19.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
